On September 30, 2025, Ocular Therapeutix, Inc. announced an underwritten offering of 37.9 million shares at $12.53 each, expecting to raise approximately $445.9 million to fund operations into 2028. The net proceeds will support product sales and expenses, including for AXPAXLI.